Gabapentin significantly improves cough symptoms in idiopathic pulmonary fibrosis (IPF) patients compared to placebo with a substantial increase in cough relief rate.
The safety profile of gabapentin in IPF cough includes manageable adverse effects such as drowsiness and dizziness, occurring in approximately one-third of treated patients.
These findings align with CHEST expert panel suggestions endorsing neuromodulators like gabapentin for refractory cough in interstitial lung disease (ILD), addressing an unmet therapeutic need.
